Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8143 · Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026. ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–104 Beneficiary protections for qualified prescription drug coverage

+23 −0Shown
More for 42 U.S.C. § 1395w–104
Read § 1395w–104Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–4(b)(3) of the Social Security Act (42 U.S.C. 1395w–104(b)(3)) is amended by adding at the end the following new subparagraph:(J) Required inclusion of certain generic drugs and biosimilar biological products.— (i) In general.— With respect to a plan year beginning on or after January 1, 2027, the formulary shall include in a preferred position relative to the reference drug— (I) each covered generic …

§ 1395w–104(b)Access to covered part D drugs(3)–(4)

Start of § 1395w–104 to (b)(3)(I) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(3)(I)(i)(i) In general(i) In general
For 2026 and each subsequent year, the PDP sponsor offering a prescription drug plan shall include each covered part D drug that is a selected drug under section 1320f–1 of this title for which a maximum fair price (as defined in section 1320f(c)(3) of this title) is in effect with respect to the year.For 2026 and each subsequent year, the PDP sponsor offering a prescription drug plan shall include each covered part D drug that is a selected drug under section 1320f–1 of this title for which a maximum fair price (as defined in section 1320f(c)(3) of this title) is in effect with respect to the year.
(3)(I)(ii)(ii) Clarification(ii) Clarification
Nothing in clause (i) shall be construed as prohibiting a PDP sponsor from removing such a selected drug from a formulary if such removal would be permitted under section 423.120(b)(5)(iv) of title 42, Code of Federal Regulations (or any successor regulation).Nothing in clause (i) shall be construed as prohibiting a PDP sponsor from removing such a selected drug from a formulary if such removal would be permitted under section 423.120(b)(5)(iv) of title 42, Code of Federal Regulations (or any successor regulation).
(3)(J)(J) [inserted: Required inclusion of certain generic drugs and biosimilar biological products.—]
(3)(J)(i)(i) [inserted: In general.—]
[inserted: With respect to a plan year beginning on or after January 1, 2027, the formulary shall include in a preferred position relative to the reference drug—]
(3)(J)(i)(I)(I) [inserted: ]
[inserted: each covered generic drug for which the wholesale acquisition cost is less than the wholesale acquisition cost of the reference drug of such covered generic drug; and]
(3)(J)(i)(II)(II) [inserted: ]
[inserted: at least two covered bio-similar biological products for which the wholesale acquisition cost is less than the wholesale acquisition cost of the reference biological product of such covered biosimilar biological product.]
(3)(J)(ii)(ii) [inserted: Prohibition on certain lim-its on access.—]
[inserted: The PDP sponsor offering the prescription drug plan may not impose limits on access to a covered generic drug required to be included on the formulary under clause (i)(I) or a covered biosimilar biological product required to be included on the formulary under clause (i)(II), including through utilization management techniques such as prior authorization, or step therapy, that are more restrictive than any such limits imposed on access to the reference drug of such covered generic drug or reference biological product of such covered biosimilar biological product, respectively, or that otherwise have the effect of limiting the availability to enrollees of such covered generic drug or covered biosimilar biological product relative to such reference drug or reference biological product over such covered generic drug or covered biosimilar biological product, respectively.]
(3)(J)(iii)(iii) [inserted: Definitions.—]
[inserted: In this subparagraph and subparagraph (J):]
(3)(J)(iii)(I)(I) [inserted: Covered biosimilar biological product.—]
[inserted: The term “covered biosimilar biological product” means a covered part D drug that is a biosimilar biological product (as defined in section 1847A(c)(6)(H)).]
(3)(J)(iii)(II)(II) [inserted: Covered generic drug.—]
[inserted: The term “covered generic drug” means a covered part D drug that is a drug described in section 1860D–2(e)(1)(A) and approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act.]
(3)(J)(iii)(III)(III) [inserted: Preferred position.—]
[inserted: The term “preferred position” means a product is placed on a more favorable formulary tier and has lower patient out-of-pocket costs than the corresponding reference drug or reference biological product.]
(3)(J)(iii)(IV)(IV) [inserted: Reference biological product.—]
[inserted: The term “reference biological product” has the meaning given such term in section 1847A(c)(6)(I).]
(3)(J)(iii)(V)(V) [inserted: Reference drug.—]
[inserted: The term “reference drug” means, with respect to a covered generic drug, the listed drug (as described in clause (i) of section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act) that is referred to in the abbreviated application for such covered generic drug under such section.]
(3)(J)(iii)(VI)(VI) [inserted: Wholesale acquisition cost.—]
[inserted: The term “wholesale acquisition cost” has the meaning given such term in section 1847A(c)(6)(B).]
(4)(4) Ensuring access during COVID–19 public health emergency period(4) Ensuring access during COVID–19 public health emergency period
(4)(A)(A) In general(A) In general
During the emergency period described in section 1320b–5(g)(1)(B) of this title, subject to subparagraph (B), a prescription drug plan or MA–PD plan shall, notwithstanding any cost and utilization management, medication therapy management, or other such programs under this part, permit a part D eligible individual enrolled in such plan to obtain in a single fill or refill, at the option of such individual, the total day supply (not to exceed a 90-day supply) prescribed for such individual for a covered part D drug.During the emergency period described in section 1320b–5(g)(1)(B) of this title, subject to subparagraph (B), a prescription drug plan or MA–PD plan shall, notwithstanding any cost and utilization management, medication therapy management, or other such programs under this part, permit a part D eligible individual enrolled in such plan to obtain in a single fill or refill, at the option of such individual, the total day supply (not to exceed a 90-day supply) prescribed for such individual for a covered part D drug.

Rest of § 1395w–104 unchanged

Step through the changes